Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249506 · ClinicalTrials.gov registry record
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 25,358
- Enrollment target
NCT03249506 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 25,358 participants.
The verdict
NCT03249506 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 25,358 participants
- Enrollment target
Study Summary
The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and established cardiovascular (CV) disease among new users of sodium-glucose co-transporter 2 inhibitor (SGLT2i) as compared with new users of non-SGLT2i anti-hyperglycemic agent (AHA).
Interventions
- DRUG Empagliflozin
- DRUG Dapagliflozin
- DRUG Canagliflozin
- DRUG Dipeptidyl Peptidase-4 Inhibitor (DPP-4)
- DRUG Glucagon-Like Peptide-1 Agonist (GLP-1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,358 participants |
| Start Date | 2016-05-12 |
| Est. Completion | 2017-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03249506
The ClinicalTrials.gov registry entry for NCT03249506 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25,358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Empagliflozin is the first listed.
NCT03249506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03249506 about?
NCT03249506 is a clinical study titled "Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)". The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and established cardiovascular (CV) disease among new users of sodium-glucose co...
What is the current status of trial NCT03249506?
This trial is currently completed. The enrollment target is 25,358 participants. The study started on 2016-05-12. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT03249506?
The interventions under investigation include: Empagliflozin (DRUG), Dapagliflozin (DRUG), Canagliflozin (DRUG), Dipeptidyl Peptidase-4 Inhibitor (DPP-4) (DRUG), Glucagon-Like Peptide-1 Agonist (GLP-1) (DRUG).
Who is sponsoring clinical trial NCT03249506?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.